HERON THERAPEUTICS INC (HRTX) Fundamental Analysis & Valuation

NASDAQ:HRTX • US4277461020

Current stock price

0.7837 USD
-0.04 (-5.02%)
At close:
0.784 USD
+0 (+0.04%)
After Hours:

This HRTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. HRTX Profitability Analysis

1.1 Basic Checks

  • HRTX had negative earnings in the past year.
  • HRTX had a negative operating cash flow in the past year.
  • In the past 5 years HRTX always reported negative net income.
  • In the past 5 years HRTX always reported negative operating cash flow.
HRTX Yearly Net Income VS EBIT VS OCF VS FCFHRTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M -200M

1.2 Ratios

  • HRTX's Return On Assets of -7.89% is amongst the best of the industry. HRTX outperforms 83.62% of its industry peers.
  • The Return On Equity of HRTX (-140.90%) is worse than 61.66% of its industry peers.
Industry RankSector Rank
ROA -7.89%
ROE -140.9%
ROIC N/A
ROA(3y)-21.14%
ROA(5y)-41.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HRTX Yearly ROA, ROE, ROICHRTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • Looking at the Gross Margin, with a value of 73.31%, HRTX belongs to the top of the industry, outperforming 82.08% of the companies in the same industry.
  • In the last couple of years the Gross Margin of HRTX has grown nicely.
  • HRTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 73.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.35%
GM growth 5Y4.39%
HRTX Yearly Profit, Operating, Gross MarginsHRTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -2K -4K -6K -8K -10K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. HRTX Health Analysis

2.1 Basic Checks

  • HRTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for HRTX has been increased compared to 1 year ago.
  • Compared to 5 years ago, HRTX has more shares outstanding
  • The debt/assets ratio for HRTX has been reduced compared to a year ago.
HRTX Yearly Shares OutstandingHRTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
HRTX Yearly Total Debt VS Total AssetsHRTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • Based on the Altman-Z score of -8.99, we must say that HRTX is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -8.99, HRTX is not doing good in the industry: 70.71% of the companies in the same industry are doing better.
  • HRTX has a Debt/Equity ratio of 9.81. This is a high value indicating a heavy dependency on external financing.
  • Looking at the Debt to Equity ratio, with a value of 9.81, HRTX is doing worse than 81.89% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 9.81
Debt/FCF N/A
Altman-Z -8.99
ROIC/WACCN/A
WACC8.22%
HRTX Yearly LT Debt VS Equity VS FCFHRTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M

2.3 Liquidity

  • HRTX has a Current Ratio of 2.48. This indicates that HRTX is financially healthy and has no problem in meeting its short term obligations.
  • HRTX has a Current ratio of 2.48. This is in the lower half of the industry: HRTX underperforms 70.33% of its industry peers.
  • HRTX has a Quick Ratio of 1.51. This is a normal value and indicates that HRTX is financially healthy and should not expect problems in meeting its short term obligations.
  • The Quick ratio of HRTX (1.51) is worse than 80.54% of its industry peers.
Industry RankSector Rank
Current Ratio 2.48
Quick Ratio 1.51
HRTX Yearly Current Assets VS Current LiabilitesHRTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. HRTX Growth Analysis

3.1 Past

  • HRTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.22%, which is quite impressive.
  • HRTX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.36%.
  • The Revenue has been growing by 11.82% on average over the past years. This is quite good.
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
Revenue 1Y (TTM)7.36%
Revenue growth 3Y12.88%
Revenue growth 5Y11.82%
Sales Q2Q%-0.47%

3.2 Future

  • HRTX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 54.91% yearly.
  • HRTX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.41% yearly.
EPS Next Y100%
EPS Next 2Y92.48%
EPS Next 3Y71.84%
EPS Next 5Y54.91%
Revenue Next Year13.78%
Revenue Next 2Y16.99%
Revenue Next 3Y18.21%
Revenue Next 5Y16.41%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
HRTX Yearly Revenue VS EstimatesHRTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
HRTX Yearly EPS VS EstimatesHRTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2027 2028 2029 2030 0 -1 -2 -3 -4

More info and screens

Find the best growth stocksShow best growing peers

1

4. HRTX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for HRTX. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HRTX Price Earnings VS Forward Price EarningsHRTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HRTX Per share dataHRTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

  • A more expensive valuation may be justified as HRTX's earnings are expected to grow with 71.84% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y92.48%
EPS Next 3Y71.84%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. HRTX Dividend Analysis

5.1 Amount

  • No dividends for HRTX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

HRTX Fundamentals: All Metrics, Ratios and Statistics

HERON THERAPEUTICS INC

NASDAQ:HRTX (3/27/2026, 8:23:53 PM)

After market: 0.784 +0 (+0.04%)

0.7837

-0.04 (-5.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-04
Inst Owners82.74%
Inst Owner Change1.11%
Ins Owners0.78%
Ins Owner Change14.48%
Market Cap147.76M
Revenue(TTM)154.90M
Net Income(TTM)-20.20M
Analysts82.22
Price Target4.42 (463.99%)
Short Float %20.03%
Short Ratio21.51
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-79.74%
Min EPS beat(2)-161.44%
Max EPS beat(2)1.96%
EPS beat(4)2
Avg EPS beat(4)-2.14%
Min EPS beat(4)-161.44%
Max EPS beat(4)246.99%
EPS beat(8)5
Avg EPS beat(8)25.98%
EPS beat(12)7
Avg EPS beat(12)19.29%
EPS beat(16)9
Avg EPS beat(16)14.84%
Revenue beat(2)1
Avg Revenue beat(2)-1.68%
Min Revenue beat(2)-4.02%
Max Revenue beat(2)0.65%
Revenue beat(4)2
Avg Revenue beat(4)-1.41%
Min Revenue beat(4)-4.22%
Max Revenue beat(4)1.93%
Revenue beat(8)4
Avg Revenue beat(8)-1.26%
Revenue beat(12)5
Avg Revenue beat(12)-0.94%
Revenue beat(16)8
Avg Revenue beat(16)0.33%
PT rev (1m)-3.7%
PT rev (3m)-3.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)100%
EPS NY rev (3m)100%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1.94%
Revenue NY rev (3m)1.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.95
P/FCF N/A
P/OCF N/A
P/B 10.31
P/tB 10.31
EV/EBITDA N/A
EPS(TTM)-0.07
EYN/A
EPS(NY)0
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.15
OCFYN/A
SpS0.82
BVpS0.08
TBVpS0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -7.89%
ROE -140.9%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 73.31%
FCFM N/A
ROA(3y)-21.14%
ROA(5y)-41.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y14.35%
GM growth 5Y4.39%
F-Score3
Asset Turnover0.61
Health
Industry RankSector Rank
Debt/Equity 9.81
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.7%
Cap/Sales 0.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.48
Quick Ratio 1.51
Altman-Z -8.99
F-Score3
WACC8.22%
ROIC/WACCN/A
Cap/Depr(3y)45.15%
Cap/Depr(5y)59.75%
Cap/Sales(3y)0.87%
Cap/Sales(5y)1.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-200%
EPS Next Y100%
EPS Next 2Y92.48%
EPS Next 3Y71.84%
EPS Next 5Y54.91%
Revenue 1Y (TTM)7.36%
Revenue growth 3Y12.88%
Revenue growth 5Y11.82%
Sales Q2Q%-0.47%
Revenue Next Year13.78%
Revenue Next 2Y16.99%
Revenue Next 3Y18.21%
Revenue Next 5Y16.41%
EBIT growth 1Y77.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-15.16%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.47%
OCF growth 3YN/A
OCF growth 5YN/A

HERON THERAPEUTICS INC / HRTX Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HERON THERAPEUTICS INC (HRTX) stock?

ChartMill assigns a fundamental rating of 2 / 10 to HRTX.


What is the valuation status of HERON THERAPEUTICS INC (HRTX) stock?

ChartMill assigns a valuation rating of 1 / 10 to HERON THERAPEUTICS INC (HRTX). This can be considered as Overvalued.


What is the profitability of HRTX stock?

HERON THERAPEUTICS INC (HRTX) has a profitability rating of 2 / 10.


What is the financial health of HERON THERAPEUTICS INC (HRTX) stock?

The financial health rating of HERON THERAPEUTICS INC (HRTX) is 2 / 10.